

May 15, 2025

To,  
**Dy. General Manager**  
Department of Corporate Services,  
BSE Ltd.,  
P. J. Towers, Dalal Street,  
Fort, Mumbai – 400 001

To,  
**The Manager – Listing,**  
National Stock Exchange of India Ltd.,  
Plot No. C/1, G Block,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

Ref: Scrip Code: 543322

Ref: Scrip Name: ALIVUS

Dear Sir/Madam,

**Sub.: Outcome of the Board Meeting**

This is to inform you that the Board of Directors (“Board”) of the Company has at its meeting held today i.e. May 15, 2025, inter-alia, recommended payment of Final Equity Dividend for the financial year 2024-25 of Rs. 5/- (250%) per equity share of Rs. 2 each, subject to the approval of shareholders at the ensuing Annual General Meeting of the Company.

This intimation is also being made available on the Company’s website at [www.alivus.com](http://www.alivus.com)

Kindly take the above on record.

Thanking you.

Yours faithfully,  
**For Alivus Life Sciences Limited**  
(formerly Glenmark Life Sciences Limited)

**Rudalf Corriea**  
**Company Secretary & Compliance Officer**

**Alivus Life Sciences Limited** (formerly Glenmark Life Sciences Limited)

**Corporate Office:**

4th Floor, OIA House, 470, Cardinal Gracious Road  
Andheri (E), Mumbai 400 099, Maharashtra, India

**Registered Office:**

Plot No 170-172, Chandramouli Industrial Estate  
Mohol Bazarpet, Solapur 413 213, India

T: +91 22 6829 7979 | CIN: L74900PN2011PLC139963 | E: [complianceofficer@alivus.com](mailto:complianceofficer@alivus.com) | W: [www.alivus.com](http://www.alivus.com)

